MPS Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 28 May 2026 | Printing & Publication | Market Cap: ₹4.9K Cr
FY’27 EBITDA guidance over INR 300 crores, implying a top line of INR 900 crores to INR 1,000 crores organically. FY’27 guidance expects EBITDA to comfortably surpass INR 300 crores, implying a 3-year EBITDA CAGR of approximately 21% from FY’24 to FY’27.
From MPS Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹2,898
Market Cap
₹4.9K Cr
P/E Ratio
26.8
How does MPS Ltd rank in Printing & Publication?
Compare MPS Ltd against every Printing & Publication company this quarter on revenue, margins and earnings-call signals.
MPS Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹205 Cr, net profit ₹47 Cr.
Full financials →📊 Revenue & Sales Performance
- →FY’27 EBITDA guidance over INR 300 crores, implying a top line of INR 900 crores to INR 1,000 crores organically.
- →Research segment expected to contribute ~55% of EBITDA, continuing its growth and high profitability.
- →Education segment (~35% of EBITDA) on a growth trajectory, boosted by AI-enabled content, accessibility services, and the Unbound acquisition expanding customer base.
- →Corporate Learning (~10% of EBITDA) turning around with investments in digital multimedia, AI-led simulations, and higher value offerings leading to stickier and longer engagements.
- →Expansion in new geographies like China, Japan, and broader APAC, leveraging platform partnerships and local collaborations.
- →AI-driven productivity and workflow transformation driving growth and margin improvement across segments.
- →High renewal rates and broadening customer base, especially from Unbound acquisition, creating predictable revenue growth.
- →Future growth supported by integrated platforms and 200+ AI engineers at MPS Labs enabling scalable capabilities.
📈 Profitability & Margins
- →FY’27 guidance expects EBITDA to comfortably surpass INR 300 crores, implying a 3-year EBITDA CAGR of approximately 21% from FY’24 to FY’27.
- →EPS is expected to comfortably surpass INR 100 crores in FY’27.
- →EBITDA split expectations for FY’27 are approximately: Research 55%, Education 35%, Corporate 10%.
- →Research segment expected to continue compounding due to scale and profitability.
- →Education is on a growth trajectory, helped by the acquisition of Unbound.
- →Corporate Learning business is turning around with stronger FY’27 prospects due to investment in digital and AI-enabled solutions.
- →EBITDA margin guidance for FY’27 is estimated in the range of 30%-35%, with margins typically expanding as revenue grows.
- →The company aims to achieve INR 1,500 crores top-line by FY’28, supporting continued earnings growth.
- →Focus remains on organic growth and disciplined inorganic acquisitions to drive earnings expansion.
🏗️ Capital Expenditure Plans
- →Capital allocation principle: capital must earn its keep within 12 months or be returned to shareholders.
- →Over FY’19 to FY’25, more than INR 650 crores of cumulative cash returned to shareholders.
- →FY’26 Board chose not to recommend a final dividend due to capital deployment in Unbound Medicine acquisition and active M&A pipeline.
- →Current focus on active M&A pipeline with 35 companies, 5 advanced, 5 live, 2 at advanced stages fitting existing segments.
- →Strategic acquisitions underway, including a Higher Ed and Online Learning carve-out in Western markets and a cross-border asset.
- →Emphasis on disciplined capital deployment on defensible growth assets with clear capabilities and customer fit.
- →Current investments focus on integrating Unbound Medicine and expanding AI-first knowledge solutions infrastructure.
- →Future capital distribution will resume post completion of deployment cycle.
💰 Fundraising & Capital Structure
- →No immediate fundraising through debt or equity explicitly mentioned.
- →The Unbound Medicine acquisition has mostly been paid for, with minor closing amounts remaining.
- →The company has a highly active and expanding M&A pipeline with about 35 companies under consideration; 5 are advanced, 5 live, and 2 at advanced stages.
- →Focus remains on disciplined acquisitions with sensible valuations and clear strategic fit.
- →Capital allocation principle: capital must earn its keep within 12 months or be returned to shareholders.
- →No final dividend recommended for FY’26 due to capital deployed in acquisitions and an active deployment cycle.
- →Distribution (dividends) will resume once the deployment cycle closes.
- →The company prioritizes organic growth and selective inorganic opportunities without announcing any immediate fundraising plans.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were MPS Ltd Q4 FY26 results?
FY’27 EBITDA guidance over INR 300 crores, implying a top line of INR 900 crores to INR 1,000 crores organically. FY’27 guidance expects EBITDA to comfortably surpass INR 300 crores, implying a 3-year EBITDA CAGR of approximately 21% from FY’24 to FY’27.
What is MPS Ltd share price analysis?
MPS Ltd currently shows a neutral. The stock trades at a P/E of 26.8 with a market cap of ₹4,916 Cr. Investors should review the full earnings analysis for detailed insights.
Is MPS Ltd planning capital expenditure?
Capital allocation principle: capital must earn its keep within 12 months or be returned to shareholders.
Keep MPS Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.